Tanuja Chitnis

List of Publications by Year
in descending order

313 papers	20,741 citations	13854 67 h-index	12585 132 g-index
321 all docs	321 docs citations	321 times ranked	17711 citing authors

#	Article	IF	Citations
1	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 2015, 85, 177-189.	1.5	3,275
2	Alterations of the human gut microbiome in multiple sclerosis. Nature Communications, 2016, 7, 12015.	5.8	957
3	International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Multiple Sclerosis Journal, 2013, 19, 1261-1267.	1.4	883
4	The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice. Journal of Experimental Medicine, 2003, 198, 63-69.	4.2	697
5	Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis. Journal of Experimental Medicine, 2003, 198, 71-78.	4.2	461
6	Increased Relapse Rate in Pediatric-Onset Compared With Adult-Onset Multiple Sclerosis. Archives of Neurology, 2009, 66, 54-9.	4.9	356
7	Body size and risk of MS in two cohorts of US women. Neurology, 2009, 73, 1543-1550.	1.5	354
8	CNS inflammation and neurodegeneration. Journal of Clinical Investigation, 2017, 127, 3577-3587.	3.9	351
9	Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nature Medicine, 2007, 13, 211-217.	15.2	342
10	Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort. JAMA Neurology, 2015, 72, 152.	4.5	328
11	Demographic and clinical features of neuromyelitis optica: A review. Multiple Sclerosis Journal, 2015, 21, 845-853.	1.4	278
12	Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurology, The, 2021, 20, 762-772.	4.9	261
13	Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. New England Journal of Medicine, 2018, 379, 1017-1027.	13.9	237
14	Regulatory functions of CD8+CD28â€“ T cells in an autoimmune disease model. Journal of Clinical Investigation, 2003, 112, 1037-1048.	3.9	236
15	Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis. Annals of Neurology, 2013, 73, 729-740.	2.8	214
16	Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Multiple Sclerosis Journal, 2009, 15, 627-631.	1.4	210
17	Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 116-127.	1.4	186
18	Age-Dependent B Cell Autoimmunity to a Myelin Surface Antigen in Pediatric Multiple Sclerosis. Journal of Immunology, 2009, 183, 4067-4076.	0.4	182

#	Article	IF	Citations
19	Smoking and Disease Progression in Multiple Sclerosis. Archives of Neurology, 2009, 66, 858-64.	4.9	182
20	Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. Journal of Clinical Investigation, 2001, 108, 739-747.	3.9	168
21	The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 520-526.	1.4	153
22	The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research. Cell, 2019, 177, 231-242.	13.5	152
23	Protecting Axonal Degeneration by Increasing Nicotinamide Adenine Dinucleotide Levels in Experimental Autoimmune Encephalomyelitis Models. Journal of Neuroscience, 2006, 26, 9794-9804.	1.7	144
24	The Role of CD4 T Cells in the Pathogenesis of Multiple Sclerosis. International Review of Neurobiology, 2007, 79, 43-72.	0.9	142
25	Elevated Neuronal Expression of CD200 Protects Wlds Mice from Inflammation-Mediated Neurodegeneration. American Journal of Pathology, 2007, 170, 1695-1712.	1.9	141
26	Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. Neurology, 2017, 88, 1623-1629.	1.5	138
27	Gut microbiota composition and relapse risk in pediatric MS: A pilot study. Journal of the Neurological Sciences, 2016, 363, 153-157.	0.3	137
28	Gestational vitamin D and the risk of multiple sclerosis in offspring. Annals of Neurology, 2011, 70, 30-40.	2.8	133
29	Work Productivity in Relapsing Multiple Sclerosis: Associations with Disability, Depression, Fatigue, Anxiety, Cognition, and Health-Related Quality of Life. Value in Health, 2012, 15, 1029-1035.	0.1	132
30	Blood neurofilament light: a critical review of its application to neurologic disease. Annals of Clinical and Translational Neurology, 2020, 7, 2508-2523.	1.7	132
31	Clinical Advances in Sex- and Gender-Informed Medicine to Improve the Health of All. JAMA Internal Medicine, 2020, 180, 574.	2.6	132
32	Clinical and MRI phenotype of children with MOG antibodies. Multiple Sclerosis Journal, 2016, 22, 174-184.	1.4	130
33	How patients with multiple sclerosis acquire disability. Brain, 2022, 145, 3147-3161.	3.7	126
34	Pediatric multiple sclerosis. Nature Reviews Neurology, 2009, 5, 621-631.	4.9	124
35	Younger children with MS have a distinct CSF inflammatory profile at disease onset. Neurology, 2010, 74, 399-405.	1.5	123
36	Differential Role of Programmed Death-Ligand 1 and Programmed Death-Ligand 2 in Regulating the Susceptibility and Chronic Progression of Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2006, 176, 3480-3489.	0.4	122

#	Article	IF	Citations
37	Exploration of machine learning techniques in predicting multiple sclerosis disease course. PLoS ONE, 2017, 12, e0174866.	1.1	122
38	Cognitive Impairment Occurs in Children and Adolescents With Multiple Sclerosis. Journal of Child Neurology, 2013, 28, 102-107.	0.7	121
39	Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology, 2009, 72, 2076-2082.	1.5	120
40	Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years. Multiple Sclerosis and Related Disorders, 2014, 3, 186-193.	0.9	116
41	Neurofilament light chain serum levels correlate with 10â€year <scp>MRI</scp> outcomes in multiple sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1478-1491.	1.7	115
42	Gut Microbiome in Progressive Multiple Sclerosis. Annals of Neurology, 2021, 89, 1195-1211.	2.8	115
43	Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. Journal of Clinical Investigation, 2001, 108, 739-747.	3.9	114
44	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology, The, 2019, 18, 185-197.	4.9	110
45	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Multiple Sclerosis and Related Disorders, 2020, 44, 102251.	0.9	110
46	Acute disseminated encephalomyelitis in 228 patients. Neurology, 2016, 86, 2085-2093.	1.5	104
47	Treatment of pediatric multiple sclerosis and variants. Neurology, 2007, 68, S54-S65.	1.5	101
48	Multiple Sclerosis Therapies in Pediatric Patients With Refractory Multiple Sclerosis. Archives of Neurology, 2011, 68, 437.	4.9	101
49	Clinical features of neuromyelitis optica in children. Neurology, 2016, 86, 245-252.	1.5	100
50	Secondary Progressive Multiple Sclerosis. Neurology, 2021, 97, 378-388.	1.5	100
51	Effect of gender on late-onset multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1472-1479.	1.4	96
52	Low testosterone is associated with disability in men with multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1584-1592.	1.4	94
53	The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis. BMC Neurology, 2019, 19, 23.	0.8	93
54	Pan-viral serology implicates enteroviruses in acute flaccid myelitis. Nature Medicine, 2019, 25, 1748-1752.	15.2	93

#	Article	IF	Citations
55	Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. Journal of Neuroimmunology, 2003, 136, 140-148.	1.1	92
56	Characteristics of Children and Adolescents With Multiple Sclerosis. Pediatrics, 2016, 138, .	1.0	89
57	CD4+ T Cells Regulate Surgical and Postinfectious Adhesion Formation. Journal of Experimental Medicine, 2002, 195, 1471-1478.	4.2	87
58	Insights Into the Molecular Pathogenesis of Progression in Multiple Sclerosis. Archives of Neurology, 2006, 63, 25.	4.9	83
59	Sexual disparities in the incidence and course of MS. Clinical Immunology, 2013, 149, 201-210.	1.4	81
60	Neuromyelitis optica spectrum disorders in children and adolescents. Neurology, 2016, 87, S59-66.	1.5	78
61	Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis. Muscle and Nerve, 2018, 58, 261-269.	1.0	78
62	Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e267.	3.1	77
63	Demographic and clinical characteristics of malignant multiple sclerosis. Neurology, 2011, 76, 1996-2001.	1.5	76
64	Polyunsaturated fatty acids and the risk of multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1830-1838.	1.4	74
65	Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 28-33.	0.9	74
66	Spinal cord lesions and clinical status in multiple sclerosis: A 1.5ÂT and 3ÂT MRI study. Journal of the Neurological Sciences, 2009, 279, 99-105.	0.3	73
67	Prenatal and Perinatal Factors and Risk of Multiple Sclerosis. Epidemiology, 2009, 20, 611-618.	1.2	72
68	CD200R1 Agonist Attenuates Mechanisms of Chronic Disease in a Murine Model of Multiple Sclerosis. Journal of Neuroscience, 2010, 30, 2025-2038.	1.7	71
69	Longitudinal evaluation of cognitive functioning in pediatric multiple sclerosis: report from the US Pediatric Multiple Sclerosis Network. Multiple Sclerosis Journal, 2014, 20, 1502-1510.	1.4	70
70	CD28-independent induction of experimental autoimmune encephalomyelitis. Journal of Clinical Investigation, 2001, 107, 575-583.	3.9	69
71	Dietary intake of vitamin D during adolescence and risk of multiple sclerosis. Journal of Neurology, 2011, 258, 479-485.	1.8	68
72	Realâ€World Effectiveness of Initial Diseaseâ€Modifying Therapies in Pediatric <scp>Multiple Sclerosis</scp>. Annals of Neurology, 2020, 88, 42-55.	2.8	68

#	Article	IF	Citations
73	Distinct effects of obesity and puberty on risk and age at onset of pediatric MS. Annals of Clinical and Translational Neurology, 2016, 3, 897-907.	1.7	67
74	Modeling Disease Severity in Multiple Sclerosis Using Electronic Health Records. PLoS ONE, 2013, 8, e78927.	1.1	67
75	Cognitive deterioration in patients with early multiple sclerosis: a 5-year study. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 38-43.	0.9	65
76	Evaluation of an Online Platform for Multiple Sclerosis Research: Patient Description, Validation of Severity Scale, and Exploration of BMI Effects on Disease Course. PLoS ONE, 2013, 8, e59707.	1.1	65
77	Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations. Nature Reviews Neurology, 2020, 16, 154-170.	4.9	65
78	The Impact of Lesion In-Painting and Registration Methods on Voxel-Based Morphometry in Detecting Regional Cerebral Gray Matter Atrophy in Multiple Sclerosis. American Journal of Neuroradiology, 2012, 33, 1579-1585.	1.2	64
79	Role of puberty in multiple sclerosis risk and course. Clinical Immunology, 2013, 149, 192-200.	1.4	64
80	Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Multiple Sclerosis Journal, 2016, 22, 935-943.	1.4	64
81	Clinical trials of disease-modifying agents in pediatric MS. Neurology, 2019, 92, e2538-e2549.	1.5	62
82	Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care. Lancet Neurology, The, 2021, 20, 136-149.	4.9	60
83	Distinct Functions of Autoreactive Memory and Effector CD4+ T Cells in Experimental Autoimmune Encephalomyelitis. American Journal of Pathology, 2008, 173, 411-422.	1.9	59
84	Tract-Based Analysis of Callosal, Projection, and Association Pathways in Pediatric Patients with Multiple Sclerosis: A Preliminary Study. American Journal of Neuroradiology, 2010, 31, 121-128.	1.2	59
85	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. JAMA Neurology, 2015, 72, 815.	4.5	59
86	High risk of postpartum relapses in neuromyelitis optica spectrum disorder. Neurology, 2017, 89, 2238-2244.	1.5	59
87	Identification of MS-specific serum miRNAs in an international multicenter study. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e491.	3.1	59
88	Dietary salt intake and time to relapse in paediatric multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1350-1353.	0.9	58
89	A case-control study of dietary salt intake in pediatric-onset multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 6, 87-92.	0.9	58
90	Cytokine Shifts and Tolerance in Experimental Autoimmune Encephalomyelitis. Immunologic Research, 2003, 28, 223-240.	1.3	57

#	Article	IF	Citations
91	Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. Neurology, 2018, 91, e1778-e1787.	1.5	55
92	Association Between Cigarette Smoking and Multiple Sclerosis. JAMA Neurology, 2020, 77, 245.	4.5	55
93	Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis. Neurology, 2014, 82, 2173-2179.	1.5	54
94	Pediatric Multiple Sclerosis. Neurologic Clinics, 2011, 29, 481-505.	0.8	53
95	Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity. JAMA Neurology, 2017, 74, 275.	4.5	52
96	Depression and fatigue in patients with multiple sclerosis. Journal of the Neurological Sciences, 2017, 380, 236-241.	0.3	52
97	Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. Journal of Allergy and Clinical Immunology, 2003, 112, 837-849.	1.5	50
98	Immunopathophysiology of pediatric CNS inflammatory demyelinating diseases. Neurology, 2016, 87, S12-9.	1.5	49
99	Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. PLoS Genetics, 2019, 15, e1007808.	1.5	48
100	Effect of vitamin D on MS activity by disease-modifying therapy class. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e167.	3.1	47
101	Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsingâ€“ remitting multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1726-1733.	1.4	46
102	Genes and Environment in Multiple Sclerosis project: A platform to investigate multiple sclerosis risk. Annals of Neurology, 2016, 79, 178-189.	2.8	45
103	Immunology of neuromyelitis optica during pregnancy. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e288.	3.1	45
104	Improved relapse recovery in paediatric compared to adult multiple sclerosis. Brain, 2020, 143, 2733-2741.	3.7	45
105	Patients report worse MS symptoms after menopause: Findings from an online cohort. Multiple Sclerosis and Related Disorders, 2015, 4, 18-24.	0.9	44
106	Pediatric multiple sclerosis. Neurology, 2016, 87, S103-9.	1.5	44
107	Daclizumab Use in Patients With Pediatric Multiple Sclerosis. Archives of Neurology, 2012, 69, 78.	4.9	43
108	Exposure to particulate matter air pollution and risk of multiple sclerosis in two large cohorts of US nurses. Environment International, 2017, 109, 64-72.	4.8	43

#	Article	IF	Citations
109	No association between dietary sodium intake and the risk of multiple sclerosis. Neurology, 2017, 89, 1322-1329.	1.5	43
110	Wearable biosensors to monitor disability in multiple sclerosis. Neurology: Clinical Practice, 2017, 7, 354-362.	0.8	43
111	Population structure and HLA DRB1*1501 in the response of subjects with multiple sclerosis to first-line treatments. Journal of Neuroimmunology, 2011, 233, 168-174.	1.1	41
112	Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients. Multiple Sclerosis Journal, 2016, 22, 1841-1849.	1.4	41
113	Maternal and Perinatal Exposures Are Associated With Risk for Pediatric-Onset Multiple Sclerosis. Pediatrics, 2017, 139, e20162838.	1.0	40
114	Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis. Multiple Sclerosis International, 2013, 2013, 1-9.	0.4	38
115	Hormone therapy use and physical quality of life in postmenopausal women with multiple sclerosis. Neurology, 2016, 87, 1457-1463.	1.5	38
116	Physical activity and the incidence of multiple sclerosis. Neurology, 2016, 87, 1770-1776.	1.5	38
117	Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis. JAMA Neurology, 2021, 78, 241.	4.5	38
118	Cognitive and patient-reported outcomes in adults with pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 354-361.	1.4	37
119	Genetic risk factors for pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1825-1834.	1.4	37
120	Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Multiple Sclerosis Journal, 2014, 20, 438-444.	1.4	36
121	Down Syndrome Disintegrative Disorder: A Clinical Regression Syndrome of Increasing Importance. Pediatrics, 2020, 145, e20192939.	1.0	36
122	Role of passive T-cell death in chronic experimental autoimmune encephalomyelitis. Journal of Clinical Investigation, 2000, 105, 1109-1116.	3.9	36
123	Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 1001-1011.	4.9	36
124	Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis. Npj Digital Medicine, 2019, 2, 123.	5.7	35
125	Temporal association of sNfL and gadâ€enhancing lesions in multiple sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 945-955.	1.7	35
126	Use of Disease-Modifying Therapies in Pediatric MS. Current Treatment Options in Neurology, 2016, 18, 36.	0.7	34

#	Article	IF	Citations
127	Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis. Journal of Neuroimaging, 2017, 27, 481-485.	1.0	34
128	Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 891-895.	1.4	32
129	Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e339.	3.1	32
130	Pediatric Neuromyelitis Optica Spectrum Disorders. Current Treatment Options in Neurology, 2018, 20, 19.	0.7	32
131	A roadmap to precision medicine for multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 522-532.	1.4	32
132	Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation. Journal of Neuroinflammation, 2015, 12, 245.	3.1	31
133	Effect of assisted reproductive technology on multiple sclerosis relapses: Case series and meta-analysis. Multiple Sclerosis Journal, 2020, 26, 1410-1419.	1.4	31
134	Social support in multiple sclerosis: Associations with quality of life, depression, and anxiety. Journal of Psychosomatic Research, 2020, 138, 110252.	1.2	31
135	Pathogenesis of Pediatric Multiple Sclerosis. Journal of Child Neurology, 2012, 27, 1394-1407.	0.7	30
136	Increased Th17 response to myelin peptides in pediatric MS. Clinical Immunology, 2013, 146, 176-184.	1.4	30
137	Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. Multiple Sclerosis and Related Disorders, 2019, 35, 119-127.	0.9	30
138	Diffusion Tensor Analysis of Pediatric Multiple Sclerosis and Clinically Isolated Syndromes. American Journal of Neuroradiology, 2013, 34, 417-423.	1.2	29
139	An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy. Multiple Sclerosis Journal, 2014, 20, 1381-1390.	1.4	29
140	Longitudinal BMI trajectories in multiple sclerosis: Sex differences in association with disease severity. Multiple Sclerosis and Related Disorders, 2016, 8, 136-140.	0.9	29
141	Urban air quality and associations with pediatric multiple sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1146-1153.	1.7	29
142	Disease-Modifying Therapy of Pediatric Multiple Sclerosis. Neurotherapeutics, 2013, 10, 89-96.	2.1	28
143	Treatment Satisfaction in Multiple Sclerosis. International Journal of MS Care, 2014, 16, 68-75.	0.4	28
144	Increased leptin and A-FABP levels in relapsing and progressive forms of MS. BMC Neurology, 2013, 13, 172.	0.8	27

#	Article	IF	Citations
145	The role of testosterone in MS risk and course. Multiple Sclerosis Journal, 2018, 24, 36-41.	1.4	27
146	Dietary factors and pediatric multiple sclerosis: A case-control study. Multiple Sclerosis Journal, 2018, 24, 1067-1076.	1.4	27
147	Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study. Npj Digital Medicine, 2020, 3, 135.	5.7	27
148	CADASIL mutation and Balo concentric sclerosis: A link between demyelination and ischemia?. Neurology, 2012, 78, 221-223.	1.5	26
149	No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50. BMC Neurology, 2013, 13, 73.	0.8	26
150	Experience with long-term rituximab use in a multiple sclerosis clinic. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2016, 2, 205521731667210.	0.5	26
151	Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 483-492.	0.9	26
152	Clostridium bolteae is elevated in neuromyelitis optica spectrum disorder in India and shares sequence similarity with AQP4. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	26
153	Challenges in the classification of pediatric multiple sclerosis and future directions. Neurology, 2007, 68, S70-S74.	1.5	25
154	Heterogeneity in association of remote herpesvirus infections and pediatric <scp>MS</scp>. Annals of Clinical and Translational Neurology, 2018, 5, 1222-1228.	1.7	25
155	Microstructural fronto-striatal and temporo-insular alterations are associated with fatigue in patients with multiple sclerosis independent of white matter lesion load and depression. Multiple Sclerosis Journal, 2020, 26, 1708-1718.	1.4	25
156	Defining Th1 and Th2 Immune Responses in a Reciprocal Cytokine Environment In Vivo. Journal of Immunology, 2004, 172, 4260-4265.	0.4	24
157	Regulation of Postsurgical Fibrosis by the Programmed Death-1 Inhibitory Pathway. Journal of Immunology, 2004, 172, 5774-5781.	0.4	24
158	Treatment of multiple sclerosis in children and adolescents. Expert Opinion on Pharmacotherapy, 2010, 11, 505-520.	0.9	24
159	Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis. Journal of Neurology, 2015, 262, 2425-2432.	1.8	24
160	Evaluating the Association between Enlarged Perivascular Spaces and Disease Worsening in Multiple Sclerosis. Journal of Neuroimaging, 2018, 28, 273-277.	1.0	24
161	History of fatigue in multiple sclerosis is associated with grey matter atrophy. Scientific Reports, 2019, 9, 14781.	1.6	24
162	The impact of a recent relapse on patient-reported outcomes in subjects with multiple sclerosis. Quality of Life Research, 2012, 21, 1677-1684.	1.5	23

#	Article	IF	Citations
163	Protective environmental factors for neuromyelitis optica. Neurology, 2014, 83, 1923-1929.	1.5	23
164	Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis. JAMA Network Open, 2021, 4, e2134627.	2.8	23
165	An expanded composite scale of MRI-defined disease severity in multiple sclerosis. NeuroReport, 2014, 25, 1156-1161.	0.6	22
166	Pediatric Multiple Sclerosis. Seminars in Neurology, 2016, 36, 148-153.	0.5	22
167	Consistent control of disease activity with fingolimod versus IFN Î²-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 91, jnnp-2019-321124.	0.9	22
168	20. Immunologic neuromuscular disorders. Journal of Allergy and Clinical Immunology, 2003, 111, S659-S668.	1.5	21
169	The US Network of Pediatric Multiple Sclerosis Centers. Journal of Child Neurology, 2015, 30, 1381-1387.	0.7	21
170	Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models. NeuroImage: Clinical, 2015, 8, 606-610.	1.4	21
171	Women's experiences of menopause in an online MS cohort: A case series. Multiple Sclerosis and Related Disorders, 2016, 9, 56-59.	0.9	21
172	Examining the contributions of environmental quality to pediatric multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 18, 164-169.	0.9	21
173	Diagnostic Considerations in Acute Disseminated Encephalomyelitis and the Interface with MOG Antibody. Neuropediatrics, 2019, 50, 273-279.	0.3	21
174	Diet quality and risk of multiple sclerosis in two cohorts of US women. Multiple Sclerosis Journal, 2019, 25, 1773-1780.	1.4	21
175	Gut microbiome is associated with multiple sclerosis activity in children. Annals of Clinical and Translational Neurology, 2021, 8, 1867-1883.	1.7	21
176	Therapeutic Strategies To Prevent Neurodegeneration And Promote Regeneration In Multiple Sclerosis. Current Drug Targets Immune, Endocrine and Metabolic Disorders, 2005, 5, 11-26.	1.8	20
177	The relationship between handedness and risk of multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 587-592.	1.4	20
178	A Putative Alzheimer's Disease Risk Allele in PCK1 Influences Brain Atrophy in Multiple Sclerosis. PLoS ONE, 2010, 5, e14169.	1.1	20
179	A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. Journal of the Neurological Sciences, 2017, 383, 221-229.	0.3	20
180	Adipokines are associated with pediatric multiple sclerosis risk and course. Multiple Sclerosis and Related Disorders, 2019, 36, 101384.	0.9	20

#	Article	IF	Citations
181	Pediatric Multiple Sclerosis. Neurologist, 2006, 12, 299-310.	0.4	19
182	A method for evaluating treatment switching criteria in multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 1483-1489.	1.4	19
183	International Pediatric MS Study Group Global Members Symposium report. Neurology, 2016, 87, S110-6.	1.5	19
184	SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. Multiple Sclerosis Journal, 2018, 24, 1485-1498.	1.4	19
185	Relapse Rate and MRI Activity in Young Adult Patients With Multiple Sclerosis: A Post Hoc Analysis of Phase 3 Fingolimod Trials. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731877861.	0.5	19
186	Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations. Multiple Sclerosis Journal, 2021, 27, 1814-1822.	1.4	19
187	Leveraging electronic health records data to predict multiple sclerosis disease activity. Annals of Clinical and Translational Neurology, 2021, 8, 800-810.	1.7	19
188	Menopause in multiple sclerosis: therapeutic considerations. Journal of Neurology, 2014, 261, 1257-1268.	1.8	18
189	Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline. Multiple Sclerosis Journal, 2020, 26, 1938-1947.	1.4	18
190	Complex relation of HLA-DRB1*1501 , age at menarche, and age at multiple sclerosis onset. Neurology: Genetics, 2016, 2, e88.	0.9	17
191	Oral contraceptives and MS disease activity in a contemporary real-world cohort. Multiple Sclerosis Journal, 2018, 24, 227-230.	1.4	17
192	Vitamin D genes influence MS relapses in children. Multiple Sclerosis Journal, 2020, 26, 894-901.	1.4	17
193	Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	17
194	Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: A longitudinal study. Journal of the Neurological Sciences, 2012, 315, 49-54.	0.3	16
195	Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count. Multiple Sclerosis and Related Disorders, 2018, 20, 51-57.	0.9	16
196	Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis. ENeurologicalSci, 2018, 12, 42-46.	0.5	16
197	Ketamine use in refractory status epilepticus associated with anti-NMDA receptor antibody encephalitis. Epilepsy and Behavior Reports, 2019, 12, 100326.	0.5	16
198	Time between expanded disability status scale (EDSS) scores. Multiple Sclerosis and Related Disorders, 2019, 30, 98-103.	0.9	16

#	Article	IF	Citations
199	Î³Î´ T Cellâ€“Secreted XCL1 Mediates Anti-CD3â€“Induced Oral Tolerance. Journal of Immunology, 2019, 203, 2621-2629.	0.4	16
200	The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 17, 47-53.	0.9	15
201	The 2D:4D ratio, a proxy for prenatal androgen levels, differs in men with and without MS. Neurology, 2015, 85, 1209-1213.	1.5	14
202	Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients. Journal of Neurology, 2018, 265, 2688-2694.	1.8	14
203	Quantitative MRI analysis of cerebral lesions and atrophy in post-partum patients with multiple sclerosis. Journal of the Neurological Sciences, 2018, 392, 94-99.	0.3	14
204	The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis. Journal of the Neurological Sciences, 2019, 403, 38-43.	0.3	14
205	Patient reported outcomes in benign multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 876-884.	1.4	13
206	Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 18, 196-201.	0.9	13
207	MRI activity in MS and completed pregnancy. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	13
208	Rotating night shift work and risk of multiple sclerosis in the Nursesâ€™ Health Studies. Occupational and Environmental Medicine, 2019, 76, 733-738.	1.3	13
209	Regional White Matter Atrophyâ^'Based Classification of Multiple Sclerosis in Cross-Sectional and Longitudinal Data. American Journal of Neuroradiology, 2009, 30, 1731-1739.	1.2	12
210	The Effect of Fingolimod on Conversion of Acute Gadoliniumâ€Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis. Journal of Neuroimaging, 2016, 26, 184-187.	1.0	12
211	Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis. International Journal of Neuroscience, 2017, 127, 971-980.	0.8	12
212	Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MSâ€MRIUS. Journal of Neuroimaging, 2018, 28, 399-405.	1.0	12
213	Multiple sclerosis and sarcoidosis. Neurology: Clinical Practice, 2019, 9, 218-227.	0.8	12
214	Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 113-121.	0.5	12
215	Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options. Expert Review of Neurotherapeutics, 2020, 20, 509-516.	1.4	12
216	Association Between Time Spent Outdoors and Risk of Multiple Sclerosis. Neurology, 2022, 98, .	1.5	12

#	Article	IF	Citations
217	Fatty acid binding protein-4 is associated with disability in multiple sclerosis patients. Multiple Sclerosis Journal, 2019, 25, 344-351.	1.4	11
218	Pediatric Multiple Sclerosis Severity Score in a large US cohort. Neurology, 2020, 95, e1844-e1853.	1.5	11
219	Early Predictors of Clinical and <scp>MRI</scp> Outcomes Using <scp>Least Absolute Shrinkage and Selection Operator (LASSO)</scp> in Multiple Sclerosis. Annals of Neurology, 2022, 92, 87-96.	2.8	11
220	Patient-reported outcomes in multiple sclerosis: Relationships among existing scales and the development of a brief measure. Multiple Sclerosis and Related Disorders, 2015, 4, 598-606.	0.9	10
221	Child Neurology: Neuromyelitis optica spectrum disorders. Neurology, 2017, 88, e10-e13.	1.5	10
222	mi RNA contributions to pediatricâ€onset multiple sclerosis inferred from GWAS. Annals of Clinical and Translational Neurology, 2019, 6, 1053-1061.	1.7	10
223	Identification of TNFAIP3 as relapse biomarker and potential therapeutic target for MOG antibody associated diseases. Scientific Reports, 2020, 10, 12405.	1.6	10
224	Interplay Between Endocrine Disruptors and Immunity: Implications for Diseases of Autoreactive Etiology. Frontiers in Pharmacology, 2021, 12, 626107.	1.6	10
225	A tale of two STAT6 knock out mice in the induction of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2009, 206, 76-85.	1.1	9
226	Improving power to detect disease progression in multiple sclerosis through alternative analysis strategies. Journal of Neurology, 2011, 258, 1812-1819.	1.8	9
227	Pediatric Demyelinating Diseases. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 1023-1045.	0.4	9
228	Paediatric MS is the same disease as adult MS: No. Multiple Sclerosis Journal, 2013, 19, 1255-1256.	1.4	9
229	Progression rates and sample size estimates for PPMS based on the CLIMB study population. Multiple Sclerosis Journal, 2015, 21, 180-188.	1.4	9
230	Removing confounding factors via constraint-based clustering: An application to finding homogeneous groups of multiple sclerosis patients. Artificial Intelligence in Medicine, 2015, 65, 79-88.	3.8	9
231	Risk attitudes and risk perceptions in individuals with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2016, 2, 205521731666540.	0.5	9
232	Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1791-1799.	1.4	9
233	Serum neurofilament levels and patientâ€reported outcomes in multiple sclerosis. Annals of Clinical and Translational Neurology, 2021, 8, 631-638.	1.7	9
234	Pediatric Central Nervous System Demyelinating Diseases. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 793-814.	0.4	9

#	Article	IF	Citations
235	A Novel Mechanism for the Immunomodulatory Functions of Class II MHCâ€“Derived Peptides. Journal of the American Society of Nephrology: JASN, 2003, 14, 1053-1065.	3.0	8
236	Using multiple imputation to efficiently correct cerebral MRI whole brain lesion and atrophy data in patients with multiple sclerosis. NeuroImage, 2015, 119, 81-88.	2.1	8
237	Acute disseminated encephalomyelitis in China, Singapore and Japan: a comparison with the USA. European Journal of Neurology, 2017, 24, 391-396.	1.7	8
238	Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate. Journal of the Neurological Sciences, 2018, 394, 127-131.	0.3	8
239	Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsingâ€“Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMSÂII Trials. Neurology and Therapy, 2019, 8, 461-475.	1.4	8
240	Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 593-602.	1.4	8
241	MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis. Journal of Neuroimaging, 2021, 31, 388-393.	1.0	8
242	Geneâ€“environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution. Multiple Sclerosis Journal, 2022, 28, 1330-1339.	1.4	8
243	Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis. Journal of the Neurological Sciences, 2011, 303, 109-113.	0.3	7
244	Functional Relapses in Pediatric Multiple Sclerosis. Journal of Child Neurology, 2014, 29, 943-946.	0.7	7
245	Cross-sectional study of smoking exposure: no differential effect on OCT metrics in a cohort of MS patients. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731982840.	0.5	7
246	Total intake of different minerals and the risk of multiple sclerosis. Neurology, 2019, 92, 10.1212/WNL.0000000000006800.	1.5	7
247	Microstructural Changes in the Left Mesocorticolimbic Pathway are Associated with the Comorbid Development of Fatigue and Depression in Multiple Sclerosis. Journal of Neuroimaging, 2021, 31, 501-507.	1.0	7
248	Triad of hypovitaminosis A, hyperostosis, and optic neuropathy in males with autism spectrum disorders. Nutritional Neuroscience, 2022, 25, 1697-1703.	1.5	7
249	Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110155.	0.5	7
250	Comparison of health-related quality of life across treatment groups in individuals with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 40, 101944.	0.9	7
251	Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study. Multiple Sclerosis and Related Disorders, 2019, 27, 65-73.	0.9	6
252	Opposing and potentially antagonistic effects of BMP and TGF-Î² in multiple sclerosis: The â€œYin and Yangâ€•of neuro-immune Signaling. Journal of Neuroimmunology, 2020, 347, 577358.	1.1	6

#	Article	IF	Citations
253	Review of Phase III Clinical Trials Outcomes in Patients with Secondary Progressive Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2021, 54, 103086.	0.9	6
254	Short Report: A Pilot Study of a Group Positive Psychology Intervention for Patients with Multiple Sclerosis. International Journal of MS Care, 2018, 20, 136-141.	0.4	6
255	Patient-reported outcomes associated with transition to secondary progressive multiple sclerosis. Quality of Life Research, 2022, 31, 1799-1805.	1.5	6
256	Symptom Interconnectivity in Multiple Sclerosis: A Narrative Review of Potential Underlying Biological Disease Processes. Neurology and Therapy, 2022, 11, 1043-1070.	1.4	6
257	B-cell depletion in children with neuroimmunologic conditions. Neurology, 2014, 83, 111-112.	1.5	5
258	BalÃ³ Concentric Sclerosis in Children. Journal of Child Neurology, 2014, 29, 603-607.	0.7	5
259	Evaluating the association of allergies with multiple sclerosis susceptibility risk and disease activity in a pediatric population. Journal of the Neurological Sciences, 2017, 375, 371-375.	0.3	5
260	Agreement analysis comparing iPad LCVA and Sloan testing in multiple sclerosis patients. Multiple Sclerosis Journal, 2018, 24, 1126-1130.	1.4	5
261	Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis. Journal of Child Neurology, 2019, 34, 148-152.	0.7	5
262	Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study. Multiple Sclerosis Journal, 2021, 27, 922-932.	1.4	5
263	The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110075.	0.5	5
264	Current international trends in the treatment of multiple sclerosis in childrenâ€"Impact of the COVID-19 pandemic. Multiple Sclerosis and Related Disorders, 2021, 56, 103277.	0.9	5
265	Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study. BMC Neurology, 2013, 13, 173.	0.8	4
266	Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy. Multiple Sclerosis Journal, 2014, 20, 757-760.	1.4	4
267	Child Neurology: Primary angiitis of the CNS. Neurology, 2017, 89, e268-e271.	1.5	4
268	Complexity of MS management in the current treatment era. Neurology, 2018, 90, 761-762.	1.5	4
269	School performance and psychiatric morbidity 6 years after pediatric acute disseminated encephalomyelitis: A nationwide population-based cohort study. Multiple Sclerosis and Related Disorders, 2019, 36, 101425.	0.9	4
270	Magnetic resonance imaging at baseline and follow-up to differentiate between pediatric monophasic acquired CNS demyelination and MS. Multiple Sclerosis and Related Disorders, 2020, 46, 102590.	0.9	4

#	Article	IF	Citations
271	Prospective growth and developmental outcomes in infants born to mothers with multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 79-89.	1.4	4
272	Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732199907.	0.5	4
273	Familial History of Autoimmune Disorders Among Patients With Pediatric Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	4
274	Temporal trends of multiple sclerosis disease activity: Electronic health records indicators. Multiple Sclerosis and Related Disorders, 2022, 57, 103333.	0.9	4
275	Preventing Multiple Sclerosis: The Pediatric Perspective. Frontiers in Neurology, 2022, 13, 802380.	1.1	4
276	Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIGMS Study. BMJ Neurology Open, 2022, 4, e000215.	0.7	4
277	Domain Induced Dirichlet Mixture of Gaussian Processes: An Application to Predicting Disease Progression in Multiple Sclerosis Patients. , 2015, , .		3
278	Strokelike Episodes in a Patient With Chronic Gait Abnormalities. JAMA Neurology, 2019, 76, 621.	4.5	3
279	Serum NFL levels should be used to monitor multiple sclerosis evolution â€“ Commentary. Multiple Sclerosis Journal, 2020, 26, 21-22.	1.4	3
280	Validation of Two Kinetic Assays for the Quantification of Endotoxin in Human Serum. Frontiers in Neurology, 2021, 12, 691683.	1.1	3
281	Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732110693.	0.5	3
282	Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2022, 62, 103793.	0.9	3
283	Joint assessment of dependent discrete disease state processes. Statistical Methods in Medical Research, 2017, 26, 1182-1198.	0.7	2
284	Early infectious exposures are not associated with increased risk of pediatric-onset multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 22, 103-107.	0.9	2
285	Clinical Course and Treatment in MOG Antibody Seropositive Children: A Case Series. Journal of Pediatric Neurology, 2019, 17, 031-037.	0.0	2
286	Aging with multiple sclerosis: A longitudinal study of physical function, mental health, and memory in two cohorts of US women. Multiple Sclerosis Journal, 2022, 28, 121-131.	1.4	2
287	Altered adipokine levels are associated with dimethyl fumarate treatment in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2021, 56, 103311.	0.9	2
288	An At-home Positive Psychology Intervention for Individuals with Multiple Sclerosis. International Journal of MS Care, 2021, 23, 128-134.	0.4	2

#	Article	IF	Citations
289	Generating real-world data from health records: design of a patient-centric study in multiple sclerosis using a commercial health records platform. JAMIA Open, 2022, 5, ooab110.	1.0	2
290	Anti-CGRP therapies for migraine in multiple sclerosis patients. Multiple Sclerosis Journal, 2022, 28, 2149-2150.	1.4	2
291	Comparison of dimethyl fumarate and interferon outcomes in an MS cohort. BMC Neurology, 2022, 22, .	0.8	2
292	Sex influences in autoimmune disease. Clinical Immunology, 2013, 149, 169.	1.4	1
293	A young man in â€œdouble-troubleâ€: Hallucinations and cranial nerve palsies. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e526.	3.1	1
294	Obesity is associated with the Optic Neuritis severity in Male patients with Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2021, 51, 102910.	0.9	1
295	GRU-DF: A Temporal Model with Dynamic Imputation for Missing Target Values in Longitudinal Patient Data. , 2020, , .		1
296	Targeting Epstein-Barr virus to treat MS. Med, 2022, 3, 159-161.	2.2	1
297	Disease modifying therapy management of multiple sclerosis after stem cell therapies: A retrospective case series. Multiple Sclerosis and Related Disorders, 2022, 63, 103861.	0.9	1
298	Patient-reported outcome measures in MS: Do development processes and patient involvement support valid quantification of clinically important variables?. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732211056.	0.5	1
299	Clinical inflammatory activity associated with response to second-line treatments in multiple sclerosis. Journal of the Neurological Sciences, 2013, 333, e409.	0.3	0
300	Removing Confounding Factors via Constraint Based Clustering: An Application to Finding Homogeneous Groups of Multiple Sclerosis Patients. , 2013, , .		0
301	Impact of MS during the critical window of brain development. Neurology, 2014, 83, 2106-2107.	1.5	0
302	OP69 â€“ 2651: Safety and effect of fingolimod on no evidence of disease activity (NEDA-4) in young adult patients with relapsing-remitting multiple sclerosis. European Journal of Paediatric Neurology, 2015, 19, S22.	0.7	0
303	Effect of Age on Clinical Outcomes in Patients Treated with Fingolimod: Pooled Analysis of Real-world Phase IV Studies. Multiple Sclerosis and Related Disorders, 2018, 26, 255.	0.9	0
304	Beyond the band: A biomarker for pediatric MS?. Multiple Sclerosis Journal, 2018, 24, 1655-1656.	1.4	0
305	Pediatric Multiple Sclerosis. , 2018, , 277-294.		0
306	1128 Sleep Apnea and Periodic Limb Movements are Highly Prevalent in Patients With Multiple Sclerosis. Sleep, 2020, 43, A429-A430.	0.6	0

#	Article	IF	Citations
307	Clinical Approach to Pediatric Demyelinating Disease. , 2021, , 469-482.		0
308	Family Perspectives on Clinical Research for Pediatric Multiple Sclerosis: Enhancing Equity. Journal of Patient Experience, 2021, 8, 237437352110393.	0.4	0
309	A-69 Baseline Predictors of Longitudinal SDMT Performance in Individuals with Multiple Sclerosis. Archives of Clinical Neuropsychology, 2021, 36, 1111-1111.	0.3	0
310	Parainfectious and Autoimmune Disorders. , 2012, , 3543-3554.		0
311	MS in Adolescence. , 2017, , 73-83.		0
312	Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis. Multiple Sclerosis International, 2020, 2020, 1-7.	0.4	0
313	Inflammatory demyelinating diseases in children: an update. Minerva Pediatrica, 2013, 65, 307-23.	2.6	0